Welcome to our dedicated page for IRADIMED SEC filings (Ticker: IRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IRADIMED's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IRADIMED's regulatory disclosures and financial reporting.
IRADIMED CORP (IRMD) director Monty K. Allen reported selling a total of 1,419 shares of common stock on September 3, 2026 in open-market or private transactions. The sales included 1,014 shares at a weighted average sale price of $86.44 per share (from trades between $86.36 and $86.54) and 405 shares at $86.35 per share. The filing states these transactions were not made under a Rule 10b5-1 trading plan and does not report Mr. Allen's remaining share holdings.
IRADIMED CORP (IRMD) received a Form 144 notice indicating that director Monty K. Allen may sell shares of the company’s common stock under Rule 144. The notice links the potential sales to RSU vesting tied to Mr. Allen’s board service in 2024 and 2025.
IRADIMED CORP (IRMD) filed an amended current report to correct a technical EDGAR item-tagging error; the underlying second-quarter 2026 results and exhibits are unchanged. Iradimed reported Q2 2026 revenue of $20.5 million, up 0.5% year over year, with GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46. Net income declined 10% to $5.2 million as gross margin eased to 74% from 78% amid the initial production ramp of the new 3870 MR IV pump. For the first half of 2026, revenue rose to $42.4 million, up 6%, and net income increased 5% to $11.0 million, while free cash flow more than doubled to $13.3 million.
The board declared a regular quarterly cash dividend of $0.20 per share, payable August 28, 2026. Management guided Q3 2026 revenue to $23.0–$24.5 million with GAAP diluted EPS of $0.49–$0.54, and reaffirmed full-year 2026 guidance for revenue of $91.0–$96.0 million and GAAP diluted EPS of $1.90–$2.05, reflecting expectations for a meaningful ramp in the 3870 pump platform and improved second-half gross margin.
IRADIMED CORPORATION, a maker of MRI‑compatible infusion pumps and patient monitors, reported Q2 2026 revenue of $20.5 million, essentially flat year over year, with net income of $5.2 million and diluted EPS of $0.41 versus $0.45 a year earlier. Gross margin declined to 74% from 78%, mainly from initial production inefficiencies on new product manufacturing. U.S. revenue fell to $16.7 million while international revenue rose to $3.7 million. Device revenue decreased on lower IV pump sales, partly offset by higher patient monitoring and Ferro Magnetic Detection Systems, while disposables and service revenue grew. For the first six months, revenue increased to $42.4 million and net income to $11.0 million.
IRADIMED ended June 30, 2026 with $59.1 million in cash and cash equivalents, contract liabilities of $7.5 million tied largely to extended maintenance agreements, and stockholders’ equity of $101.7 million. Operating cash flow for the first half was $14.2 million, while capital spending moderated after prior facility expansion. Cash dividends declared for the first half totaled about $5.1 million, and a further quarterly dividend of $0.20 per share was approved for payment on August 28, 2026. Management expects higher full‑year 2026 revenue but also higher operating expenses, and reports no material legal matters or control weaknesses.
IRADIMED CORPORATION reported Q2 2026 revenue of $20.5 million, up 0.5% from the same quarter in 2025, with net income of $5.2 million and GAAP diluted EPS of $0.41, both below the prior-year $5.8 million and $0.45.
For the first six months of 2026, revenue was $42.4 million, up 6% year over year, with net income of $11.0 million and GAAP diluted EPS of $0.86, both higher than 2025. Non-GAAP diluted EPS was $0.46 for Q2 and $0.95 for the first half.
The company emphasized the initial launch and production ramp of its next-generation 3870 MRI-compatible IV infusion pump, record domestic monitor bookings, and gross margins of 74% in Q2 and 75% year-to-date. Operating cash flow was $5.9 million in Q2 and $14.2 million for the first half. IRADIMED declared a regular quarterly cash dividend of $0.20 per share payable August 28, 2026, and reaffirmed full-year 2026 guidance for revenue of $91.0–$96.0 million and GAAP diluted EPS of $1.90–$2.05.
BlackRock, Inc. reported a passive ownership stake in IRADIMED CORP common stock on a Schedule 13G. As of June 30, 2026, BlackRock beneficially owned 641,128 shares, representing 5.01% of the outstanding common stock.
BlackRock reported sole voting power over 622,925 shares and sole dispositive power over 641,128 shares, with no shared voting or dispositive power. The filing notes that various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of IRADIMED’s outstanding common shares.
Iradimed Corporation reported the results of its annual stockholder meeting. Stockholders elected Roger Susi, Monty Allen, Joe Kiani, Hilda Scharen-Guivel and James Hawkins to the board of directors. They also ratified RSM US LLP as independent auditor for the fiscal year ending December 31, 2026, and approved an advisory resolution on executive compensation.
IRADIMED CORP CFO John Glenn reported routine equity compensation activity. On June 20, 2026, he exercised 5,796 restricted stock units into the same number of common shares. To cover related tax obligations, 2,319 shares of common stock were disposed of as a tax-withholding transaction, not an open-market sale. After these entries, he directly holds 11,937 shares of IRADIMED common stock.
IRADIMED CORP director Hilda Frederique Scharen-Guivel sold 3,000 shares of Common Stock in open-market transactions at $95.00 per share. The sales occurred on June 4, 2026. Footnotes state that the shares she continues to hold were acquired through the vesting and settlement of restricted stock units granted for her board service.
IRMD submitted a notice under Form 144 reporting a proposed sale of 285,000 shares of Common Stock. The filing lists securities related to RSU vesting (1,766 shares on 10/14/2023 and 1,234 shares on 10/14/2024 and shows 12,783,035 shares outstanding as of 06/04/2026.